Hypothalamic-pituitary-adrenal system regulation in recently detoxified alcoholics is not altered by one week of treatment with acamprosate

Pharmacopsychiatry

Volumn 37, Issue 3, 2004, Pages 98-102

  Zimmermann, U ^a   Spring, K ^a   Koller, G ^b   Holsboer, F ^a   Soyka, M ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; CORTICOTROPIN; HYDROCORTISONE;

ADULT; ALCOHOL WITHDRAWAL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; CORTICOTROPIN TEST; FEMALE; HORMONAL REGULATION; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; PRIORITY JOURNAL; SAMPLE SIZE; WITHDRAWAL SYNDROME;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; CASE-CONTROL STUDIES; CORTICOTROPIN-RELEASING HORMONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PITUITARY-ADRENAL SYSTEM; TAURINE; TREATMENT OUTCOME;

EID: 2542445478     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-818986     Document Type: Article

References (29)

1. Adinoff B, Martin PR, Bone GHA, Eckardt MJ, Roehrich L, George DT, Moss HB, Eskay R, Linnoila M, Gold PW. Hypothalamic-pituitary-adrenal axis functioning and cerebrospinal fluid corticotropin releasing hormone and corticotropin levels in alcoholics after recent and long-term abstinence. Arch Gen Psychiat 1990; 47: 325-330
2. al Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotective against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res 2001; 25: 1276-1283
3. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998; 22: 183-191
4. Brady KT, Sonne SC. The role of stress in alcohol use, alcoholism treatment, and relapse. Alcohol Res Health 1999; 23: 263-271
5. Dahchour A, De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343-362
6. Feuerlein W, Ringer C, Kufner H, Antons K. Diagnosis of alcoholism: the Munich Alcoholism Test (MALT). Curr Alcohol 1979; 7: 137-147
7. Gerra G, Caccavari R, Delsignore R, Vourna S, Maestri D, Ugolotti G, Passeri M. Pituitary responses to Ca-acetyl-homotaurinate in normal subjects and alcoholics. Neuroendocrinol Lett. 1992; 14: 119-126
8. Heinz A, Jones DW, Bissette G, Hommer D, Ragan P, Knable M, Wellek S, Linnoila M, Weinberger DR. Relationship between cortisol and serotonin metabolites and transporters in alcolholism. Pharmacopsychiatry 2002; 35: 127-134
9. Heyser CJ, Schulteis G, Durbin P, Koob GF. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats. Neuropsychopharmacology 1998; 18: 125-133
10. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
11. Hundt W, Zimmermann U, Pöttig M, Hahn K, Holsboer F. The combined dexamethasone suppression/ CRH stimulation test in alcoholics during and after acute withdrawal. Alcohol Clin Exp Res 2001; 25: 687-691
12. Jezova D, Tokarev D, Rusnak M. Endogenous excitatory amino acids are involved in stress-induced adrenocorticotropin and catecholamine release. Neuroendocrinology 1995; 62: 326-332
13. Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl- D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 1996; 20: 651-658
14. Mayer S, Harris BR, Gibson DA, Blanchard JA, Prendergast MA, Holley RC, Littleton J. Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. Alcohol Clin Exp Res 2002; 26: 1468-1478
15. Naassila M, Hammoumi S, Legrand E, Durbin P, Daoust M. Mechanism of action of acamprosate. Part I. Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 1998; 22: 802-809
16. Oliver C, Jezova D, Grino M et al., Brann DW, Mahesh VB, editors. Excitatory amino acids. Their role in neuroendocrine function. 1 ed. Vol. 5, Excitatory amino acids and the hypothalamic-pituitary-adrenal axis. Boca Raton: CRC Press, 1996: 167-185
17. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo- controlled dose-finding study. Br J Psychiat 1997; 171: 73-77
18. Popp RL, Lovinger DM. Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons. Eur J Pharmacol 2000; 394: 221-231
19. Rammes G, Mahal B, Putzke J, Parsons C, Spielmanns P, Pestel E, Spanagel R, Zieglgansberger W, Schadrack J. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001; 40: 749-760
20. Ravi SD, Dorus W, Park YN, Collins MC, Reid RW, Borge GF. The dexamethasone suppression test and depressive symptoms in early and late withdrawal from alcohol. Am J Psychiat 1984; 141: 1445-1448
21. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiat 1996; 53: 673-680
22. Schule C, Laakmann G, Baghai T, Neukam C, Soyka M. Lack of effects of acamprosate on anterior pituitary hormone secretion in healthy subjects [letter]. J Clin Psychopharmacol 1999; 9: 387-389
23. Spanagel R, Hölter SM, Allingham K, Landgraf R, Zieglgansberger W. Acamprosate and alcohol. 1. Effects on alcohol intake following alcohol deprivation in the rat. Eur J Pharmacol 1996; 305: 39-44
24. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-1357
25. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiat 1995; 152: 332-340
26. Wetterling T, Veltrup C, Junghanns K, Kromer-Olbrisch T, Schneider U. Acceptance of pharmacotherapy for relapse prevention by chronic alcoholics. Pharmacopsychiatry 2001; 34: 142-146
27. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker W. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1995; 347: 1438-1442
28. Zimmermann U, Hundt W, Spring K, Grabner A, Holsboer F. Hypothalamic-pituitary-adrenal system adaptation to detoxification in alcohol-dependent patients is affeced by family history of alcoholism. Biol Psychiat 2003; 53: 75-84
29. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response to the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: A prospective study. J Psychiat Res 2001; 35: 83-94